Table 2.
Univariate and Multivariate analyses in patients (n=91) with chemotherapy
| EFS | OS | |||
|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Univariate analysis | ||||
| RhoBTB3 (High vs Low) | 0.569 (0.356-0.909) | 0.018 | 0.518 (0.320-0.838) | 0.007 |
| age (≥60 vs <60) | 3.375 (1.937-5.879) | <0.001 | 3.156 (1.792-5.560) | <0.001 |
| Gender (Male vs Female) | 1.036 (0.655-1.640) | 0.879 | 1.168 (0.730-1.868) | 0.518 |
| WBC (≥100 vs <100×109) | 1.247 (0.620-2.508) | 0.537 | 1.328 (0.658-2.681) | 0.428 |
| RUNX1 mutation(Yes vs No) | 1.539 (0.736-3.221) | 0.252 | 1.673 (0.798-3.508) | 0.173 |
| TP53 mutation (Yes vs No) | 3.217 (1.645-6.292) | 0.001 | 3.136 (1.608-6.115) | 0.001 |
| ASXL1 mutation (Yes vs No) | 1.840 (0.573-5.912) | 0.306 | 1.857 (0.579-5.956) | 0.298 |
| NPM1 mutation (Yes vs No) | 1.211 (0.742-1.975) | 0.443 | 1.046 (0.631-1.733) | 0.861 |
| FLT3-ITD mutation (Yes vs No) | 1.057 (0.556-2.008) | 0.866 | 0.832 (0.413-1.676) | 0.606 |
| biCEBPA mutation (Yes vs No) | 0.388 (0.054-2.798) | 0.348 | 0.427 (0.059-3.080) | 0.399 |
| Multivariate analysis | ||||
| RhoBTB3 (High vs Low) | 0.576 (0.359-0.922) | 0.022 | 0.501 (0.307-0.818) | 0.006 |
| age (≥60 vs <60) | 3.607 (1.973-6.595) | <0.001 | 3.352 (1.817-6.187) | <0.001 |
| WBC (≥100 vs <100×109) | 2.361 (1.112-5.011) | 0.025 | 2.495 (1.171-5.320) | 0.018 |
| TP53 mutation (Yes vs No) | 2.341 (1.173-4.670) | 0.016 | 2.503 (1.247-5.026) | 0.010 |
| ASXL1 mutation (Yes vs No) | - | - | 3.343 (1.004-11.134) | 0.049 |